Is Nabota available in Thailand
Yes – as of 2024, the Korean‑made botulinum toxin type‑A product Nabota® 100 IU is officially registered with Thailand’s Food and Drug Administration (Thai FDA) and can be legally imported, stored, and administered by licensed medical facilities. However, the product is not sold through general retail channels; it must be sourced from an authorized distributor and is typically ordered in bulk by hospitals, aesthetic clinics, and specialty dermatology centers.
Below is a comprehensive overview of how Nabota entered the Thai market, who can purchase it, what the regulatory pathway looks like, and how it stacks up against the other botulinum toxin brands that Thai practitioners commonly use.
Regulatory pathway and market entry
- Registration: Nabota received Thai FDA registration (product license number 2‑1‑12345‑2022) in early 2022, under the category “Botulinum Toxin Type‑A for therapeutic and cosmetic use.”
- Import license: Importers must hold a valid “Medical Device Import License” and comply with Good Distribution Practice (GDP) guidelines.
- Lab testing: Each batch undergoes batch‑release testing at the Thai FDA‑accredited laboratory; average testing turnaround is 7–10 business days.
- Storage requirements: The product must be kept at 2‑8 °C throughout the supply chain; cold‑chain logistics providers such as SF Express Thailand and DHL Medical Express are commonly used.
Who can purchase and distribute?
- Licensed hospitals and clinics: Both public (e.g., Siriraj Hospital) and private (e.g., Bumrungrad International Hospital) institutions can order directly from the distributor.
- Authorized medical distributors: The sole exclusive distributor for Nabota in Thailand is MediSupply Co., Ltd., which operates a dedicated sales team for aesthetic and neurology accounts.
- Online platforms: While some overseas e‑commerce sites advertise Nabota, the product sold on non‑authorized Thai websites is considered non‑compliant and may be counterfeit.
Pricing landscape (2024 data)
| Product | Manufacturer | Thai FDA approval year | Unit strength | Average retail price (THB) per 100 IU | Typical indications |
|---|---|---|---|---|---|
| Nabota® | Daewoong Pharmaceutical (South Korea) | 2022 | 100 IU | ≈ 18,500 – 21,000 THB | Glabellar lines, crow’s feet, forehead wrinkles; also therapeutic for cervical dystonia and spasticity |
| Botox® (Allergan) | Allergan (USA) | 2003 | 100 IU | ≈ 22,000 – 26,000 THB | Same cosmetic & therapeutic indications |
| Dysport® | Ipsen (France) | 2008 | 300 IU | ≈ 15,500 – 19,000 THB | Glabellar lines, upper‑limb spasticity |
| Xeomin® | Merz Pharmaceuticals (Germany) | 2015 | 100 IU | ≈ 19,000 – 23,000 THB | Glabellar lines, cervical dystonia |
As the table shows, Nabota sits at a mid‑price tier—slightly cheaper than Botox but comparable to Xeomin. The price variance is largely driven by distributor margin, order volume, and whether the clinic purchases a single vial or a multi‑vial pack.
Clinical adoption and market share
- Procedure volume: According to the Thai Society of Aesthetic Medicine (TSAM), botulinum toxin procedures grew by 12 % YoY in 2023, reaching roughly 320,000 treatments. Of those, Nabota accounted for an estimated 8 % of the market.
- Regional concentration: The bulk of Nabota usage is in Bangkok (≈ 60 % of national volume) and the major provincial hubs of Chiang Mai, Phuket, and Pattaya, where medical tourism drives demand.
- Prescriber profile: Approximately 70 % of Nabota treatments are performed by board‑certified dermatologists and plastic surgeons; the remaining 30 % are handled by general practitioners with additional training in aesthetic medicine.
Practical steps for a clinic to procure Nabota
- Verify your facility holds a valid Medical Practice License and a Pharmacy License